Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Michon

Showing results (251-260 of 256) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 256 results.
British Journal of Cancer|September 4, 2008
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma GroupB De Bernardi, V Mosseri, H Rubie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie PédiatriqueH Rubie, O Hartmann, J Michon, et al.
International Journal of Cancer|March 27, 2001
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplificationD Plantaz, J Vandesompele, N Van Roy, et al.
British Journal of Cancer|September 20, 2000
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncologyV Minard, O Hartmann, M C Peyroulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Quality assessment of genetic markers used for therapy stratificationI M Ambros, J Benard, M Boavida, et al.
British Journal of Cancer|December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)G Schleiermacher, J Michon, A Ribeiro, et al.
Pageof 26

Showing results (251-260 of 256) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 256 results.
British Journal of Cancer|September 4, 2008
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma GroupB De Bernardi, V Mosseri, H Rubie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie PédiatriqueH Rubie, O Hartmann, J Michon, et al.
International Journal of Cancer|March 27, 2001
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplificationD Plantaz, J Vandesompele, N Van Roy, et al.
British Journal of Cancer|September 20, 2000
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncologyV Minard, O Hartmann, M C Peyroulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Quality assessment of genetic markers used for therapy stratificationI M Ambros, J Benard, M Boavida, et al.
British Journal of Cancer|December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)G Schleiermacher, J Michon, A Ribeiro, et al.
Pageof 26